[{"id":"22583c54-e88b-4929-8c51-cddb83c29f34","acronym":"ATLAS-IT-04","url":"https://clinicaltrials.gov/study/NCT03725605","created_at":"2023-12-09T16:26:37.013Z","updated_at":"2024-07-02T16:35:27.172Z","phase":"Phase 2","brief_title":"LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)","source_id_and_acronym":"NCT03725605 - ATLAS-IT-04","lead_sponsor":"Lytix Biopharma AS","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oncopore (ruxotemitide)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 07/02/2021","primary_completion_date":" 07/02/2021","study_txt":" Completion: 10/11/2021","study_completion_date":" 10/11/2021","last_update_posted":"2023-12-05"},{"id":"aa242778-1644-4871-9ae6-baf20f40061c","acronym":"ATLAS-IT-05","url":"https://clinicaltrials.gov/study/NCT04796194","created_at":"2021-03-12T15:53:01.676Z","updated_at":"2024-07-02T16:35:29.830Z","phase":"Phase 2","brief_title":"Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma","source_id_and_acronym":"NCT04796194 - ATLAS-IT-05","lead_sponsor":"Lytix Biopharma AS","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Oncopore (ruxotemitide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-09"}]